Current status and future applications of cellular therapies for cancer

Immunotherapy

Volumn 3, Issue 4, 2011, Pages 507-516

  Copier, John ^a   Bodman Smith, Mark ^a   Dalgleish, Angus ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

ACT; adoptive therapy; cancer immunotherapy; dendritic cell vaccine; T cell

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; B7 ANTIGEN; BARDOXOLONE METHYL; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACLIZUMAB; DCVAX; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; DEXAMETHASONE; FLUDARABINE; GEMCITABINE; INTERLEUKIN 12; INTERLEUKIN 2; IPLIMUMAB; LENALIDOMIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLACEBO; POMALIDOMIDE; PROVENGE; TAMOXIFEN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADOPTIVE T LYMPHOCYTE THERAPY; ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TREATMENT FAILURE; GAMMA DELTA T LYMPHOCYTE; HUMAN; IMMUNOMODULATION; IMMUNOPOTENTIATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MELANOMA; NONHUMAN; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; THERAPY EFFECT; TREATMENT RESPONSE; WHOLE BODY RADIATION;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 79953834363     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.11.18     Document Type: Review

References (67)

1. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM: Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol. Immunother. 58, 1-14 (2009). Overview of dendritic cell (DC) vaccines in melanoma patients, demonstrating both the achievable clinical efficacy and the variability in outcome of vaccination.
2. Ilett EJ, Prestwich RJ, Melcher AA: The evolving role of dendritic cells in cancer therapy. Expert Opin. Biol. Ther. 10, 369-379 (2010).
3. Lesterhuis WJ, Aarntzen EH, De Vries IJ et al.: Dendritic cell vaccines in melanoma: from promise to proof? Crit. Rev. Oncol. Hematol. 66, 118-134 (2008).
4. + progenitors and activated with type I interferon. J. Immunother. 28, 505-516 (2005).
5. Simon T, Fonteneau JF, Gregoire M: Dendritic cell preparation for immunotherapeutic interventions. Immunotherapy 1, 289-302 (2009).
6. Gottfried E, Kreutz M, Mackensen A: Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev. 19, 65-77 (2008).
7. Nizar S, Copier J, Meyer B et al.: T-regulatory cell modulation: the future of cancer immunotherapy? Br. J. Cancer 100, 1697-1703 (2009).
8. Jacobs JF, Punt CJ, Lesterhuis WJ et al.: Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a Phase I/II study in metastatic melanoma patients. Clin. Cancer Res. 16, 5067-5078 (2010).
9. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56, 641-648 (2007).
10. Liu P, Jaffar J, Hellstrom I, Hellstrom KE: Administration of cyclophosphamide changes the immune profile of tumor-bearing mice. J. Immunother. 33, 53-59 (2010).
11. Robert C, Ghiringhelli F: What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist 14, 848-861 (2009).
12. Hodi FS, O'Day SJ, McDermott DF et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
13. Pilon-Thomas S, Mackay A, Vohra N, Mule JJ: Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J. Immunol. 184, 3442-3449 (2010).
14. Nagaraj S, Youn JI, Weber H et al.: Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin. Cancer Res. 16, 1812-1823 (2010).
15. Liu WM, Fowler DW, Smith P, Dalgleish AG: Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br. J. Cancer 102, 115-123 (2010).
16. Chiarella P, Vulcano M, Bruzzo J et al.: Anti-inflammatory pretreatment enables an efficient dendritic cell-based immunotherapy against established tumors. Cancer Immunol. Immunother. 57, 701-718 (2008).
17. Lemoine FM, Cherai M, Giverne C et al.: Massive expansion of regulatory T-cells following interleukin 2 treatment during a Phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. Int. J. Oncol. 35, 569-581 (2009).
18. Schwaab T, Schwarzer A, Wolf B et al.: Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (interleukin 2) and IFN-a2a therapy in metastatic renal cell carcinoma patients. Clin. Cancer Res. 15, 4986-4992 (2009).
19. Svane IM, Pedersen AE, Nikolajsen K, Zocca MB: Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2. Vaccine 26, 4716-4724 (2008).
20. Trepiakas R, Berntsen A, Hadrup SR et al.: Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a Phase I/II trial. Cytotherapy 12, 721-734 (2010).
21. Higano CS, Schellhammer PF, Small EJ et al.: Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115, 3670-3679 (2009).
22. Copier J, Dalgleish AG, Britten CM et al.: Improving the efficacy of cancer immunotherapy. Eur. J. Cancer 45, 1424-1431 (2009).
23. Hoos A, Parmiani G, Hege K et al.: A clinical development paradigm for cancer vaccines and related biologics. J. Immunother. 30, 1-15 (2007).
24. Rosenberg SA, Dudley ME: Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 21, 233-240 (2009).
25. Dudley ME, Wunderlich JR, Robbins PF et al.: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854 (2002).
26. Goff SL, Smith FO, Klapper JA et al.: Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J. Immunother. 33, 840-847 (2010). Data from Phase III clinical trials of sipuleucel-T, an autologous DC vaccine, which has recently been awarded a licence in the USA for the treatment of advanced prostate cancer.
27. + cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. J. Immunother. 33, 547-556 (2010).
28. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA: Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26, 332-342 (2003).
29. Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP: Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 26, 111-117 (2005).
30. Salem ML, Cole DJ: Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination. Cancer Immunol. Immunother. 59, 341-353 (2010). Original study in melanoma patients showing that tumor-derived T cells could produce both clinical and immunological effects.
31. Dudley ME, Wunderlich JR, Yang JC et al.: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23, 2346-2357 (2005).
32. Wrzesinski C, Paulos CM, Kaiser A et al.: Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J. Immunother. 33, 1-7 (2010).
33. Dudley ME, Yang JC, Sherry R et al.: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233-5239 (2008).
34. Wallen H, Thompson JA, Reilly JZ et al.: Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS One 4, E4749 (2009).
35. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl Acad. Sci. USA 102, 9571-9576 (2005).
36. + T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118, 294-305 (2008).
37. Michalek J, Kocak I, Fait V, Zaloudik J, Hajek R: Detection and long-term in vivo monitoring of individual tumor-specific T cell clones in patients with metastatic melanoma. J. Immunol. 178, 6789-6795 (2007).
38. Johnson LA, Morgan RA, Dudley ME et al.: Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535-546 (2009). Differences in clinical outcome achievable through alteration of host environment prior to adoptive therapy. This was related to intensity of lymphodepletion.
39. + T cells mediate superior antitumor immunity. Proc. Natl Acad. Sci. USA 106, 17469-17474 (2009).
40. Merlo A, Turrini R, Dolcetti R et al.: The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica 95, 1769-1777 (2010).
41. Yee C: Adoptive therapy using antigen-specific T-cell clones. Cancer J. 16, 367-373 (2010).
42. Khammari A, Labarriere N, Vignard V et al.: Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J. Invest. Dermatol. 129, 2835-2842 (2009).
43. Warren EH, Fujii N, Akatsuka Y et al.: Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 115, 3869-3878 (2010).
44. Frankel TL, Burns WR, Peng PD et al.: Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J. Immunol. 184, 5988-5998 (2010).
45. + T cells exhibit multifunctional effector and helper responses, in vitro. Clin. Immunol. 136, 338-347 (2010).
46. Jena B, Dotti G, Cooper LJ: Redirecting T-cell specificity by introducing a tumorspecific chimeric antigen receptor. Blood 116, 1035-1044 (2010).
47. Burns WR, Zhao Y, Frankel TL et al.: A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res. 70, 3027-3033 (2010).
48. Morgan RA, Yang JC, Kitano M et al.: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843-851 (2010).
49. Morgan RA, Dudley ME, Wunderlich JR et al.: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129 (2006).
50. Koike N, Pilon-Thomas S, Mule JJ: Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma. J. Immunother. 31, 402-412 (2008). Along with references [51] and [52] demonstrates the potential synergy between DC vaccination and T-cell therapy.
51. Lou Y, Wang G, Lizee G et al.: Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res. 64, 6783-6790 (2004). Along with references [50] and [52] demonstrates the potential synergy between DC vaccination and T-cell therapy.
52. + T cell/regulatory T cells in tumour. Clin. Exp. Immunol. 162, 75-83 (2010). Along with references [50] and [51] demonstrates the potential synergy between DC vaccination and T-cell therapy.
53. Kondo H, Hazama S, Kawaoka T et al.: Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res. 28, 379-387 (2008).
54. Kobayashi H, Tanaka Y, Yagi J et al.: Safety profile and anti-tumor effects of adoptive immunotherapy using γ-δ T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol. Immunother. 56, 469-476 (2007).
55. Bennouna J, Bompas E, Neidhardt EM et al.: Phase-I study of Innacell γδ, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol. Immunother. 57, 1599-1609 (2008).
56. Nakajima J, Murakawa T, Fukami T et al.: A Phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous γδ T cells. Eur. J. Cardiothorac. Surg. 37, 1191-1197 (2010).
57. Noguchi A, Kaneko T, Kamigaki T et al.: Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors. Cytotherapy 13(1), 92-97 (2010).
58. Wilhelm M, Kunzmann V, Eckstein S et al.: γδ T cells for immune therapy of patients with lymphoid malignancies. Blood 102, 200-206 (2003).
59. Dieli F, Vermijlen D, Fulfaro F et al.: Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 67, 7450-7457 (2007). Analysis of peripheral γδ T-cell activation and phenotype in patients treated with aminobisphosphonates. Demonstrates that it is possible to manipulate γδ T cells without the need for ex vivo culture.
60. Gnant M, Mlineritsch B, Schippinger W et al.: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormomeresponsive, stage I and II breast cancer: first efficacy results from ABCSG-12. Presented at: ASCO Annual Meeting Chicago, IL, USA 30 May-3 June 2008.
61. Santini D, Martini F, Fratto ME et al.: In vivo effects of zoledronic acid on peripheral γδ T lymphocytes in early breast cancer patients. Cancer Immunol. Immunother. 58, 31-38 (2009).
62. Meraviglia S, Eberl M, Vermijlen D et al.: In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin. Exp. Immunol. 161, 290-297 (2010).
63. Laggner U, Lopez JS, Perera G et al.: Regression of melanoma metastases following treatment with the N-bisphosphonate zoledronate and localised radiotherapy. Clin. Immunol. 131, 367-373 (2009).
64. Dalgleish A, Galustian C: The potential of immunomodulatory drugs in the treatment of solid tumors. Future Oncol. 6, 1479-1484 (2010).
65. Galustian C, Meyer B, Labarthe MC et al.: The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol. Immunother. 58, 1033-1045 (2009).
66. Grange JM, Krone B, Stanford JL: Immunotherapy for malignant melanoma - tracing Ariadne's thread through the labyrinth. Eur. J. Cancer 45, 2266-2273 (2009).
67. Stanford JL, Stanford CA, O'Brien ME, Grange JM: Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur. J. Cancer 44, 224-227 (2008).